Amgen Inc - Asset Resilience Ratio
Amgen Inc (AMGN) has an Asset Resilience Ratio of 11.26% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Amgen Inc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2023)
This chart shows how Amgen Inc's Asset Resilience Ratio has changed over time. See Amgen Inc book value and equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Amgen Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Amgen Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $10.94 Billion | 11.26% |
| Total Liquid Assets | $10.94 Billion | 11.26% |
Asset Resilience Insights
- Moderate Liquidity: Amgen Inc has 11.26% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Amgen Inc Industry Peers by Asset Resilience Ratio
Compare Amgen Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AstraZeneca PLC
NASDAQ:AZN |
Drug Manufacturers - General | 5.03% |
|
Novartis AG
MX:NVSN |
Drug Manufacturers - General | 0.09% |
|
Novartis AG ADR
NYSE:NVS |
Drug Manufacturers - General | 10.03% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 7.18% |
|
Virbac SA
PA:VIRP |
Drug Manufacturers - General | 0.23% |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019 |
Drug Manufacturers - General | 0.53% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 8.63% |
Annual Asset Resilience Ratio for Amgen Inc (1999–2023)
The table below shows the annual Asset Resilience Ratio data for Amgen Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 11.26% | $10.94 Billion | $97.15 Billion | +8.69pp |
| 2022-12-31 | 2.57% | $1.68 Billion | $65.12 Billion | +2.50pp |
| 2021-12-31 | 0.08% | $48.00 Million | $61.16 Billion | -6.88pp |
| 2020-12-31 | 6.96% | $4.38 Billion | $62.95 Billion | +2.15pp |
| 2019-12-31 | 4.81% | $2.87 Billion | $59.71 Billion | -28.85pp |
| 2018-12-31 | 33.67% | $22.36 Billion | $66.42 Billion | -13.71pp |
| 2017-12-31 | 47.37% | $37.88 Billion | $79.95 Billion | +2.49pp |
| 2016-12-31 | 44.89% | $34.84 Billion | $77.63 Billion | +6.83pp |
| 2015-12-31 | 38.05% | $27.24 Billion | $71.58 Billion | +4.30pp |
| 2014-12-31 | 33.76% | $23.30 Billion | $69.01 Billion | +10.17pp |
| 2013-12-31 | 23.59% | $15.60 Billion | $66.12 Billion | -14.73pp |
| 2012-12-31 | 38.31% | $20.80 Billion | $54.30 Billion | +10.29pp |
| 2011-12-31 | 28.02% | $13.70 Billion | $48.87 Billion | -4.48pp |
| 2010-12-31 | 32.50% | $14.13 Billion | $43.49 Billion | +5.86pp |
| 2009-12-31 | 26.64% | $10.56 Billion | $39.63 Billion | +5.30pp |
| 2008-12-31 | 21.34% | $7.78 Billion | $36.44 Billion | +6.54pp |
| 2007-12-31 | 14.80% | $5.13 Billion | $34.64 Billion | +0.02pp |
| 2006-12-31 | 14.78% | $4.99 Billion | $33.79 Billion | +3.12pp |
| 2005-12-31 | 11.66% | $3.42 Billion | $29.30 Billion | -3.00pp |
| 2004-12-31 | 14.65% | $4.28 Billion | $29.22 Billion | -1.72pp |
| 2003-12-31 | 16.37% | $4.29 Billion | $26.18 Billion | +4.88pp |
| 2002-12-31 | 11.50% | $2.81 Billion | $24.46 Billion | -19.13pp |
| 2001-12-31 | 30.62% | $1.97 Billion | $6.44 Billion | -2.74pp |
| 2000-12-31 | 33.37% | $1.80 Billion | $5.40 Billion | +3.88pp |
| 1999-12-31 | 29.48% | $1.20 Billion | $4.08 Billion | -- |
About Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women wi… Read more